Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ НИИ фармакологии им. В.В.Закусова РАМН, Москва
Список исп. литературыСкрыть список 1. Schleifer SJ et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 1785–9. 2. Смулевич А.Б. Депрессии при сердечно-сосудистых заболеваниях. Психич. расстройства в общей медицине. 2013; 3: 4–9. 3. Whooley MA et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008; 300: 2379–88. 4. Gottlieb SS et al. The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 2004; 43: 1542–9. 5. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation 2005; 111: 250–3. 6. Taylor CB et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiat 2005; 62: 792–8. 7. Медведев В.Э. Профилактика и терапия психопатологических расстройств у пациентов с сердечно-сосудистыми заболеваниями. Неврология, нейропсихиатрия, психосоматика. 2012; 3: 54–9. 8. Glassman AH et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701–9. 9. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiat 1985; 46: 42–4. 10. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894–8. 11. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011; 9. 12. Bhuiyan MS et al. Targeting sigma-1-receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Expert Opin Ther Targets 2010; 14 (10): 1009–22. 13. Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr 2004; 9: 23–31. 14. Ishikawa M et al. High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [11C] SA4503. Biol Psychiat 2007; 62: 878–83. 15. Hashimoto K. s1-Receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009; 9: 197–204. 16. Minamino T, Komuro I, Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res 2010; 107: 1071–82. 17. Minamino T, Kitakaze M. ER stress in cardiovascular disease. J Mol Cell Cardiol 2010; 48: 1105–10. 18. Su TP et al. The s1-receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010; 31: 557–66. 19. Hayashi T et al. Targeting ligand-operated chaperone s1-receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2011; 15: 557–77. 20. Groenendyk J et al. Biology of endoplasmic reticulum stress in the heart. Circ Res 2010; 107: 1185–97. 21. Dickhout JG, Carlisle RE, Austin RC. Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: Endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res 2011; 108: 629–42. 22. Морозов П.В. Энигма s-рецепторов. Психиатр. и психофармакотер. им. П.Б.Ганнушкина. 2009; 2: 58–60. 23. Романов Д.В. s1-Рецепторы как потенциальная мишень психофармакотерапии. Психиатр. и психофармакотер. им. П.Б.Ганнушкина. 2011; 6: 56–60. 24. Медведев В.Э. Cигма-рецепторы: роль в лечении аффективных расстройств. Неврология, нейропсихиатрия, психосоматика. 2012; 2: 105. 25. Ito K et al. Decreased brain s1-receptor contributes to the relationship between heart failure and depression. Cardiovasc Res 2012; 93 (1): 33–40. 26. Bhuiyan MS, Fukunaga K. Stimulation of s1-receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats. Expert Opin Ther Targets 2009; 13 (11): 1253–65. 27. Ela C et al. Sigma-receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 1994; 269: 1300–9. 28. Tagashira H et al. s1-Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am J Physiol Heart Circ Physiol 2010; 299 (5): H1535–45. 29. Tagashira H et al. Distinct cardioprotective effects of 17b-estradiol and dehydroepiandrosterone on pressure overload-induced hypertrophy in ovariectomized female rats. Menopause 2011; 18 (12): 1317–26. 30. Narita N et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307: 117–9. 31. Fujimoto M et al. s1-Receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse 2012; 66: 630–9. 32. Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the s1-receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett 2008; 440: 19–22. 33. Sen S, Duman R, Sanacora G. Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications. Biol Psychiat 2008; 64: 527–32. 34. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169–80. 35. Bocchio-Chiavetto L et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiat 2010; 11: 763–73. 36. Manni L et al. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 2005; 102: 169–71. 37. Ejiri J et al. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation 2005; 112: 2114–20. 38. Jiang H et al. Association of plasma brain-derived neurotrophic factor and cardiovascular risk factors and prognosis in angina pectoris. Biochem Biophys Res Commun 2011; 415: 99–103.